Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin Alfa Dosing in Anemic Low/Int-1 Risk MDS
NCT00446602Phase 2Withdrawn
- Sponsor
- Johnson & Johnson
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
A Phase 2 trial of epoetin alfa in anemia, sponsored by Johnson & Johnson. Status: withdrawn.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00446602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00446602.